CA2561952A1 - Use of 5,10-methylene tetrahydrofolate for the treatment of cancer - Google Patents

Use of 5,10-methylene tetrahydrofolate for the treatment of cancer Download PDF

Info

Publication number
CA2561952A1
CA2561952A1 CA002561952A CA2561952A CA2561952A1 CA 2561952 A1 CA2561952 A1 CA 2561952A1 CA 002561952 A CA002561952 A CA 002561952A CA 2561952 A CA2561952 A CA 2561952A CA 2561952 A1 CA2561952 A1 CA 2561952A1
Authority
CA
Canada
Prior art keywords
cancer
anticancer drug
additional anticancer
dosage
milligrams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002561952A
Other languages
English (en)
French (fr)
Inventor
Joan M. Robbins
Mark J. Cantwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savara Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2561952A1 publication Critical patent/CA2561952A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002561952A 2004-04-02 2005-04-01 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer Abandoned CA2561952A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US55888904P 2004-04-02 2004-04-02
US60/558,889 2004-04-02
US62547904P 2004-11-04 2004-11-04
US60/625,479 2004-11-04
US65874505P 2005-03-04 2005-03-04
US60/658,745 2005-03-04
PCT/US2005/011046 WO2005097086A2 (en) 2004-04-02 2005-04-01 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA2561952A1 true CA2561952A1 (en) 2005-10-20

Family

ID=35125596

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002561952A Abandoned CA2561952A1 (en) 2004-04-02 2005-04-01 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer

Country Status (7)

Country Link
US (1) US20070280944A1 (cg-RX-API-DMAC7.html)
EP (1) EP1740182A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007531728A (cg-RX-API-DMAC7.html)
AU (1) AU2005231436A1 (cg-RX-API-DMAC7.html)
CA (1) CA2561952A1 (cg-RX-API-DMAC7.html)
IL (1) IL178261A0 (cg-RX-API-DMAC7.html)
WO (1) WO2005097086A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871279B2 (en) * 2000-03-09 2014-10-28 Yale University Use of the combination of PHY906 and a tyrosine kinase inhibitor as a cancer treatment regimen
ES2373867T3 (es) 2007-03-02 2012-02-09 The University Of Wollongong Composiciones y procedimientos para el suministro de agentes anticancerosos.
WO2008109349A1 (en) * 2007-03-06 2008-09-12 Adventrx Pharmaceuticals, Inc. Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine
RU2482496C2 (ru) * 2008-09-26 2013-05-20 Эститю Де Кансероложи Де Л'Вест Оптимизация индивидуальных доз 5-фторурацила при режиме folfox
EP2341908B1 (en) * 2008-09-26 2016-04-13 Institut de Cancérologie de l'Ouest (I.C.O) Individual 5-fluorouracile dose optimization in folfiri treatment
EP2617422A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate
EP2617421A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer
WO2018065445A1 (en) * 2016-10-05 2018-04-12 Isofol Medical Ab [6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
WO2018065446A1 (en) * 2016-10-05 2018-04-12 Isofol Medical Ab [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
EP3305318A1 (en) * 2016-10-05 2018-04-11 Isofol Medical AB [6r]-5,10-methylenetetrahydrofolate in 5-fluorouracil based chemotherapy
EP3446703A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
EP3446704A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
WO2018150264A1 (en) * 2017-02-14 2018-08-23 Isofol Medical Ab METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION
MX2020007009A (es) * 2018-01-05 2020-11-11 Isofol Medical Ab Metodos para tratar canceres colorrectales metastasicos y colorrectales.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376658A (en) * 1990-05-11 1994-12-27 University Of Southern California 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy

Also Published As

Publication number Publication date
WO2005097086A3 (en) 2006-05-18
JP2007531728A (ja) 2007-11-08
EP1740182A2 (en) 2007-01-10
US20070280944A1 (en) 2007-12-06
WO2005097086A2 (en) 2005-10-20
AU2005231436A1 (en) 2005-10-20
IL178261A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
Seiwert et al. The concurrent chemoradiation paradigm—general principles
Diamond et al. Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy
De Stefano et al. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients
Braun et al. New systemic frontline treatment for metastatic colorectal carcinoma
Overman et al. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors
US20070280944A1 (en) Use of 5,10-Methylene Tetrahydrofolate for the Treatment of Cancer
JP2015536950A (ja) Tecファミリーキナーゼ阻害剤アジュバント療法
BR112019016668A2 (pt) métodos para aumentar a concentração de plasma de durd e para inibir timidilato-sintase (ts) em um indivíduo humano.
JP2021526161A (ja) 癌治療のための方法及び医薬組成物
Budman Capecitabine
Garland et al. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors
JP6174044B2 (ja) Egfr阻害剤と組み合わせたテトラヒドロフォレート
EP3456354A1 (en) New anti-malignant tumor agent based on specificity of cancer cell metabolism
RU2689557C2 (ru) Применение фармацевтической композиции для лечения или создания условий ремиссии у пожилого пациента с солидным раком
US20210379095A1 (en) Methods and Combination Therapy to Treat Biliary Tract Cancer
Sarantopoulos et al. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study
Jeong et al. Doxifluridine versus Tegafur/Gimeracil/Oteracil (S-1) as adjuvant chemotherapy for patients with gastric cancer after gastrectomy: a propensity score-matched analysis
RU2482496C2 (ru) Оптимизация индивидуальных доз 5-фторурацила при режиме folfox
KR20070019725A (ko) 암치료에 사용되는 5,10-메틸렌 테트라하이드로폴레이트의용도
Azzoli et al. Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial
Ricart et al. Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors
Ge et al. Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells
EP3801547A1 (en) Methods of treating cancer
Melichar et al. Urinary neopterin in patients with metastatic colon cancer treated with patupilone
JP7414230B2 (ja) 抗血液悪性腫瘍薬

Legal Events

Date Code Title Description
FZDE Discontinued